Background: Airway epithelial injury is a crucial component of acute and severe
| INTRODUCTION
Asthma is a complex disorder that involves an intricate interplay between structural 1 and immune cells. 2 Current therapeutics available for asthma are based on the inflammatory response; however, they are ineffective for a group of patients, who develop resistance. 3 Therefore, there is an imperative need to target alternative pathways of asthma pathogenesis. 4 In contrast to immune cells, the airway epithelial layer is a structural boundary between the lung and the external environment, and current literature suggests that airway epithelial injury is a critical aspect of asthma pathogenesis. 1, 5 Stressed epithelia produce cytokines such as TSLP, IL-33, and IL-25, 2 which can cause airway inflammation and remodeling. 6 Of these, TSLP has gained the most importance in asthma. 7 Importantly, overexpression of TSLP in the lungs of na€ ıve mice led to self-perpetuated asthma-like features. 8 Interestingly, in a recent report, treatment with tezepelumab, a monoclonal antibody against TSLP, was found to be effective in severe asthma patients with poor steroid responsiveness. 9 Further, apoptosis of bronchial epithelial cells (BECs) in the lungs of human asthmatics 10, 11 and in mice with experimental asthma, reported by us 12, 13 and others, 14 suggests the involvement of epithelial stress in asthma.
Hence, finding out the pathways involved in the survival or damage of airway epithelial cells could be a suitable approach for the discovery of alternative therapies in asthma management. 3 ) are positively charged biological molecules at physiological pH. 15 PA catabolism plays a crucial role in maintaining optimal levels of intracellular PA pools by converting longer PAs back to smaller PAs through two key catabolic enzymes, spermidine/spermine-N(1)-acetyltransferase-1 (SAT1) and spermine oxidase (SMOX) ( Figure 1A ). 16 SAT1 transfers acetyl F I G U R E 1 Loss of the PA catabolic enzymes SAT1 and SMOX in human asthmatics and in mice with allergic airway inflammation (AAI). A, Schematic depiction of PA metabolism. PUT is synthesized by oxidative decarboxylation of ornithine by the ornithine decarboxylase (ODC). PUT further gets converted into SPD and SPM by spermidine synthase (SRM) and spermine synthase (SMS), respectively. PA catabolism converts longer PAs back to smaller PAs through SAT1, SMOX, and PAOX. Key enzymes are in filled shapes, and pharmacological modulators are italicized. B, Representative Western blots and densitometry of SAT1 and SMOX in human lung lysates (n = 4). C,D, Representative IHC images of SAT1 and SMOX in human lung sections (n = 4; Original magnification: 2009). E, Schematic presentation of the protocols for the OVA-induced AAI model without (Set-I) and with (Set-II-Set-IV) different modulators of PA catabolism, see Methods. F, PA levels in the whole lung lysates of mice. G, Representative Western blots for catabolic enzymes (SAT1 and SMOX) in whole lung lysates. H, Representative IHC images of SAT1 and SMOX in lungs sections of mice (Original magnification: 2009). In images, arrows indicate expression in BECs. All data are presented as means AE SEM Mice data (F-H, means AE SEM) are representative from one of three independent experiments (n = 5). Student's t test, *P < .05; **P < .01 [Colour figure can be viewed at wileyonlinelibrary.com]
G R A P H I C A L A B S T R A C T
Polyamine catabolic enzymes, SAT1 and SMOX, are reduced in asthma. Polyamine accumulation contributes to increased bronchial epithelial fragility in asthma. Drugs or genetic modulation that increases polyamine catabolism are effective in models of asthma.
groups onto SPM and SPD, and acetylated PAs are either exported out of the cell or oxidized by acetyl polyamine oxidase (PAOX Figure 1A ). 19 The involvement of PA pathway in cell survival or death has been reported. 20, 21 However, the effects of PAs are contextual, depending on their concentrations and cell types. 22 In asthma, PA levels are increased in the blood 23 and sputum (especially SPM) 24 
| MATERIALS AND METHODS
For a detailed description, please see Supplementary section.
| Animals
Male BALB/c mice (8-10 weeks old) were obtained from Central Drug Research Institute (Lucknow, India) and acclimatized for a week before the experiments. Animals were maintained following the guidelines and protocols approved by the institutional animal ethics committee.
| Human samples
Human lung lysates and paraffin-embedded lung sections (from same samples) were purchased from Novus Biologicals (Colorado, USA)
and BioChain Institute, Inc. (California, USA).
| Cell line
Human bronchial epithelial cell line, BEAS-2B (derived from normal human bronchial epithelium) 28 was purchased (CRL-9609; ATCC, USA) and grown in serum-free LHC-9 medium (Gibco, USA 
| Statistical analysis
Statistical analyses were performed using GraphPad Prism software.
One-way ANOVA test was used to compare more than two groups followed by Tukey's post hoc analysis. Between two groups, unpaired, two-tailed Student's t test was used. 
| PA catabolism is downregulated in AAI
To study the role of derailed PA metabolism in epithelial injury and, thus, asthma pathogenesis, we used murine-model of AAI, which shows key features of asthma ( Figure 1E : Set-I). To confirm the suitability of the model, we checked the levels of PAs by high-performance liquid chromatography (HPLC) and the expression of ODC, SAT1, and SMOX by Western blotting. To estimate the levels of PAs, lung tissues from mice with AAI (OVA/OVA) and normal mice (SHAM/PBS) were used. We found a significant increase in the levels of all mammalian PAs, PUT, SPD, and SPM, in mice with AAI ( Figure 1F ). However, of all PAs, the levels of SPM were increased the most (~2 fold) ( Figure 1F ). Although no differences were observed in ODC ( Figure S1B ), SAT1 and SMOX levels were significantly reduced ( Figure 1G and Figure S1C ,D). Additionally, the activity of SAT1 was decreased ( Figure S1E ). These results were confirmed by IHC which showed that SAT1 and SMOX were downregulated predominantly in BECs ( Figure 1H and Figure S1F ). Induction of PA catabolism reduced high levels of SPM and SPD in the lungs of mice with AAI ( Figure 3C ). It also reduced AHR (Figure 3D ) and improved histopathological features, such as airway inflammation ( Figure 3E ,F), goblet cell metaplasia and sub-epithelial collagen deposition ( Figure 3E ). Further, BENSPM treatment led to a reduction in BAL eosinophils and neutrophils to nearly undetectable levels ( Figure 3G ). Interestingly, these mice also showed a marked reduction in TSLP levels ( Figure 3H ), indicating alleviation of BEC stress. This reversal of asthma features and epithelial stress was associated with a striking reduction in ova-specific IgE ( Figure 3I) and pro-inflammatory cytokines, IL-4, IL-5, and IL-13 ( Figure 3J -L).
|
As a greater level of epithelial stress has been reported in severe asthmatics than in intermittent asthma patients, 34 we sought to further increase the levels of SPM and SPD in the lungs of mice with AAI using inhibitors of SAT1 and SMOX, BERENIL 
| SPM is the most active PA in inducing apoptosis of human BECs
After finding a strong correlation between accumulation of SPM and apoptosis of BECs in the lungs, we tested the causal role of each PA in inducing apoptosis of BEAS-2B cells by culturing them with different concentrations of PUT, SPD, and SPM. The extent of apoptosis was quantified using AnnexinV/7-AAD assay. Of the PAs, SPM was found to be the most active PA in inducing the apoptosis of BEAS-2B, followed by SPD, whereas PUT was ineffective ( Figure 6A ,B). To determine whether the apoptosis of BEAS-2B was due to the dysfunction of mitochondria, we measured cyto c, in the cytosols of BEAS-2B. Cyto c levels were increased with increasing concentrations of SPM ( Figure 6C ). Moreover, the cleavage of csp-3 showed a concentration-dependent increase ( Figure 6D ).
| DISCUSSION
Normally, PAs are tightly maintained at levels optimal for cellular functions. Alterations in PA levels, either high 21, 23, 24, 30, 37, 38 or low, 21, 39 have been associated with various diseases. In asthma, integrin was shown to reduce AHR by catabolizing PAs locally. 42 However, in the absence of integrin, this effect was not observed even after induction of SAT1. Moreover, SAT1 expression in ASMCs was not tested in asthma. In contrast to ASMCs, we found predominant reduction of SAT1 in BECs. Hence, the induction of asthma-like features after knockdown is likely due to BEC stress ( Figure 5A ). 8, 12 In contrast to knockdown experiments, overexpression of either SAT1 or SMOX alleviated AAI with BEC stress; this further strengthens the importance of both enzymes in asthma. Further, we found worsening of asthmatic features in AAI after SAT1 and SMOX inhibition using BERENIL and MDL72527, respectively, that was associated with higher levels of SPM, BEC stress and apoptosis. This aggravated response could be implicated in severe asthmatic conditions, where airway epithelial shedding is greater than in mild intermittent asthma. 34 Induction of PA catabolism appears to be a viable therapeutic approach in asthma. BENSPM treatment reduced PAs and potently alleviated AAI along with epithelial stress. The striking reduction in OVA-specific IgE levels after BENSPM treatment could be due to reduced TSLP levels, as TSLP stimulates T cells to express IL-4 43 that is known to induce IgE synthesis from B cells in asthma. 44 While it
is not possible to definitively separate the interlinked inflammatory response and epithelial stress in AAI, the overall data are consistent with BENSPM alleviating BEC injury by reducing PA accumulation, thereby attenuating the release of TSLP and damping the wellknown feed-forward loop between AAI and epithelial injury.
Recently, an antibody against TSLP markedly inhibited exacerbations in severe asthmatics and reduced IgE levels. 9 Importantly, this effect was independent of asthma subtypes such as eosinophilic or neutrophilic. This suggests that therapeutic interventions targeting BEC stress and TSLP release may be most relevant for severe asthmatics.
Restoring normal PA catabolism seems to be one such approach.
Moreover, the effects of BENSPM treatment are consistent with observations in Parkinson's disease model, where BENSPM induced SAT1 reduced PAs and alleviated disease pathology, while BERENIL worsened it. 30 In contrast, in tumor lines, BENSPM induced PA catabolism from hundreds to thousands-fold and resulted in cytotoxicity, 45, 46 whereas in our study BENSPM did not induce SAT-1 activity to such an extent and thus reduced epithelial stress.
In a study by North et al, an attempt was made to inhibit PA biosynthesis using DFMO. However, that strategy could not reduce high levels of SPM and targeting ODC worsened AAI and peri-bronchial collagen deposition in mice, although it attenuated AHR. 24 The reason for these unexpected results could be (i) the observed unchanged levels of ODC in AAI, and (ii) inability of DFMO to consistently reduce SPM levels, due to additional compensatory mechanisms and incomplete inhibition of ODC. 47, 48 Thus, there was no effect on SPM levels in their model, and the observed changes in AHR could be because of SPD levels. SPM was the most effective PA in inducing AHR in their study and in inducing BEC injury in our study. In contrast, our strategy of using BENSPM did bring down the elevated levels of SPM and alleviated asthmatic features.
Bronchial epithelial cells are damaged and sensitive to apoptosis in the lungs of asthmatics 10, 11 and in mice with OVA-induced AAI, as reported by us and others. [12] [13] [14] 49 Thus, we speculated that these high levels of PAs could lead to apoptosis of BECs. In our in vivo models with modulated PA catabolism, we found high levels of SPM are representative from one of at least three independent experiments (ANOVA test followed by Tukey's post hoc analysis, *P < .05; **P < .01; ***P < .001) [Colour figure can be viewed at wileyonlinelibrary.com] F I G U R E 5 SPM accumulation in the lungs positively correlates with the apoptosis of BECs. A-C, Representative images of TUNEL assay and quantification of TUNEL-positive BECs after SAT1 and SMOX modulations in mice, that is, after (A) knock down by shRNA, (B) induction using BENSPM and (C) overexpression by their respective plasmids. D, Linear regression plots and Pearson's correlation coefficients for the percentage of apoptotic BECs with respect to SPM, SPD and PUT levels in the lungs for different murine models used in this study. E-G, Representative Western blots of cyto c and c-csp-3 in the lung cytosols after SAT1 and SMOX modulations, that is, after (E) knock down by shRNA, (F) induction using BENSPM and (G) overexpression by plasmids. Br, bronchus. Arrows indicate TUNEL-positive BEC nuclei in brown (original magnification, 10009). Data (means AE SEM) are representative from one of two independent experiments (n = 5-6; ANOVA test followed by Tukey's post hoc analysis, **P < .01; ***P < .001) [Colour figure can be viewed at wileyonlinelibrary.com]
